Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Checkpoint inhibitors more effective in men than women

Conforti F et al. Lancet Oncol. 2018 May 16. doi: 10.1016/S1470-2045(18)30261-4

Publish date:: June 26, 2018

Key clinical point: Checkpoint inhibitors are linked with greater mortality reductions in men than in women.

Major finding: Checkpoint inhibitors are associated with a 28% reduction in cancer mortality in men and 14% in women.

Study details: Systematic review and meta-analysis of 20 randomized, controlled trials involving 11,351 patients.

Disclosures: No funding or conflicts of interest were declared.

Read the article.

Citation:

Conforti F et al. Lancet Oncol. 2018 May 16. doi: 10.1016/S1470-2045(18)30261-4

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Renal Cell Carcinoma

Study shows no link between race and mortality in clear cell RCC,

Four factors may predict better survival with cabozantinib in mRCC,

Fear of recurrence highly prevalent in RCC survivors,

Risk factors for severe immune-related AEs identified,

Pembrolizumab plus axitinib continues to outshine sunitinib for advanced RCC,